Journal of Surgery Concepts & Practice >

2024 , Vol. 29 >Issue 02: 114 - 120

DOI: https://doi.org/10.16139/j.1007-9610.2024.02.04

Experts forum

Recent advances in subtyping of biliary tract carcinoma

Expand
  • 1. Department of Hepatobiliary Surgery, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fujian Fuzhou 350025, China
    2. Fujian Province Liver Disease Research Center, Fujian Fuzhou 350025, China
    3. Department of Hepatobiliary Surgery, the First Affiliated Hospital of Fujian Medical University, Fujian Fuzhou 350005, China

Received date: 2024-03-12

  Online published: 2024-07-01

Fold

Abstract

Biliary tract carcinoma exhibits high heterogeneity at the genomic, epigenetic, and molecular expression levels. The patients even with the same pathological morphology and clinical stage of biliary tract malignant tumors have substantial differences in the treatment response and prognosis. Traditional pathological histology and clinical classifications are no longer sufficient to meet the demands of the precision medicine era. Molecular subtyping has the potential to provide more personalized cancer treatment strategies. It not only helps to reveal the mechanisms of tumor development and accurately predict disease prognosis, but also plays a crucial role in guiding the development of novel targeted drugs and implementing targeted therapies for specific tumors. With the ongoing development of precision medicine, the role of molecular subtyping in cancer diagnosis, treatment option, and prognosis assessment is increasingly prominent. This paper systematically reviewed the recent progress in the molecular subtyping of biliary tract malignant tumors based on domestic and international clinical and basic research.

Key words： Biliary tract carcinoma; Clinical classification; Pathological histology classification; Molecular subtyping; Precision therapy

Cite this article

LIN Zhiwen, LIU Hongzhi, ZENG Yongyi . Recent advances in subtyping of biliary tract carcinoma[J]. Journal of Surgery Concepts & Practice, 2024 , 29(02) : 114 -120 . DOI: 10.16139/j.1007-9610.2024.02.04

References

[1] SCOTT A J, SHARMAN R, SHROFF R T. Precision medicine in biliary tract cancer[J]. J Clin Oncol, 2022, 40(24):2716-2734.
[2] YIN L, ZHAO S, ZHU H, et al. Primary tumor resection improves survival in patients with multifocal intrahepatic cholangiocarcinoma based on a population study[J]. Sci Rep, 2021, 11(1):12166.
[3] RUZZENENTE A, BAGANTE F, OLTHOF P B, et al. Surgery for Bismuth-Corlette type 4 perihilar cholangiocarcinoma: results from a western multicenter collaborative group[J]. Ann Surg Oncol, 2021, 28(12):7719-7729.
[4] DING G, YANG Y, CAO L, et al. A modified Jarnagin-Blumgart classification better predicts survival for resectable hilar cholangiocarcinoma[J]. World J Surg Oncol, 2015,13:99.
[5] 李秉璐, 吴昕. 国内外有关肝内胆管癌分型分期解读[J]. 中国实用外科杂志, 2020, 40 (6):656-660.
  LI B L, WU X. Interpretation of classification and staging of intrahepatic cholangiocarcinoma at home and abroad[J]. Chin J Pract Surg, 2020, 40 (6):656-660.
[6] 中华医学会外科学分会胆道外科学组, 中国医师协会外科医师分会胆道外科专业委员会. 胆囊癌诊断和治疗指南(2019版)[J]. 中华外科杂志, 2020, 58(4):243-251.
  Biliary Surgery Group of the Surgical Credit Association of the Chinese Medical Association, Biliary Surgery Professional Committee of the Surgical Branch of the Chinese Medical Association. Guidelines for diagnosis and treatment of gallbladder cancer (2019 edition)[J]. Chin J Surg, 2020, 58(4):243-251.
[7] 中国抗癌协会胆道肿瘤专业委员会. 中国抗癌协会胆道恶性肿瘤靶向及免疫治疗指南(2022)(简要版)[J]. 中国实用外科杂志, 2023, 43(5):481-491.
  Biliary Tumor Professional Committee of China Anti Cancer Association. Chinese anti cancer association guidelines for targeting and immunotherapy of biliary malignant tumors (2022) (brief edition)[J]. Chin J Pract Surg, 2023, 43(5):481-491.
[8] NAGTEGAAL I D, ODZE R D, KLIMSTRA D, et al. The 2019 WHO classification of tumours of the digestive system[J]. Histopathology, 2020, 76(2):182-188.
[9] 罗方秀, 马乾宸, 袁菲. 第5版WHO消化系统肿瘤分类解读:胆道系统肿瘤的更新及进展[J]. 外科理论与实践, 2023, 28(2):124-131.
  LUO F X, MA Q C, YUAN F. Interpretation of the 5th edition of WHO classification of digestive system tumors: updates and progress on biliary system tumors[J]. J Surg Concepts Pract, 2023, 28(2):124-131.
[10] SILVERMAN I M, HOLLEBECQUE A, FRIBOULET L, et al. Clinicogenomic analysis of FGFR2-rearranged cho-langiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib[J]. Cancer Discov, 2021, 11(2):326-339.
[11] VALLE J W, KELLEY R K, NERVI B, et al. Biliary tract cancer[J]. Lancet, 2021, 397(10272):428-444.
[12] ZOU S, LI J, ZHOU H, et al. Mutational landscape of intrahepatic cholangiocarcinoma[J]. Nat Commun, 2014,5:5696.
[13] DONG L, LU D, CHEN R, et al. Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma[J]. Cancer Cell, 2022, 40(1):70-87.e15.
[14] CHEN X, WANG D, LIU J, et al. Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes[J]. J Immunother Cancer, 2021, 9(11):e003214.
[15] LIN J, CAO Y, YANG X, et al. Mutational spectrum and precision oncology for biliary tract carcinoma[J]. The-ranostics, 2021, 11(10):4585-4598.
[16] GOEPPERT B, TOTH R, SINGER S, et al. Integrative analysis defines distinct prognostic subgroups of intrahepatic cholangiocarcinoma[J]. Hepatology, 2019, 69(5):2091-2106.
[17] JAVLE M, BEKAII-SAAB T, JAIN A, et al. Biliary cancer: utility of next-generation sequencing for clinical management[J]. Cancer, 2016, 122(24):3838-3847.
[18] SONG G, SHI Y, MENG L, et al. Publisher correction: single-cell transcriptomic analysis suggests two molecularly distinct subtypes of intrahepatic cholangiocarcinoma[J]. Nat Commun, 2022, 13(1):2848.
[19] SIA D, HOSHIDA Y, VILLANUEVA A, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes[J]. Gastroenterology, 2013, 144(4):829-840.
[20] LI H, QU L, YANG Y, et al. Single-cell transcriptomic architecture unraveling the complexity of tumor heterogeneity in distal cholangiocarcinoma[J]. Cell Mol Gastroenterol Hepatol, 2022, 13(5):1592-1609.
[21] MONTAL R, SIA D, MONTIRONI C, et al. Molecular classification and therapeutic targets in extrahepatic cho-langiocarcinoma[J]. J Hepatol, 2020, 73(2):315-327.
[22] BAO X, LI Q, CHEN J, et al. Molecular subgroups of intrahepatic cholangiocarcinoma discovered by single-cell RNA sequencing-assisted multiomics analysis[J]. Cancer Immunol Res, 2022, 10(7):811-828.
[23] DENG M, RAN P, CHEN L, et al. Proteogenomic characterization of cholangiocarcinoma[J]. Hepatology, 2023, 77(2):411-429.
[24] LAPITZ A, AZKARGORTA M, MILKIEWICZ P, et al. Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma[J]. J Hepatol, 2023, 79(1):93-108.
[25] YI X, ZHU J, LIU W, et al. Proteome landscapes of human hepatocellular carcinoma and intrahepatic cholangiocarcinoma[J]. Mol Cell Proteomics, 2023, 22(8):100604.
[26] YU W L, YU G, DONG H, et al. Proteomics analysis identified TPI1 as a novel biomarker for predicting recurrence of intrahepatic cholangiocarcinoma[J]. J Gastroenterol, 2020, 55(12):1171-1182.
[27] CHANG T T, HO C H. Plasma proteome atlas for diffe-rentiating tumor stage and post-surgical prognosis of hepatocellular carcinoma and cholangiocarcinoma[J]. PLoS One, 2020, 15(8):e0238251.
[28] 童焕军, 汤朝晖, 全志伟. 肝内胆管癌异常脂质代谢研究进展[J]. 中华肝脏外科手术学电子杂志, 2020, 9(6):501-506.
  TONG H J, TANG Z H, QUAN Z W. Research progress on abnormal lipid metabolism in intrahepatic cholangiocarcinoma[J]. Chin J Hepat Surg(Electronic Edition), 2020, 9(6):501-506.
[29] HANAHAN D. Hallmarks of cancer: new dimensions[J]. Cancer Discov, 2022, 12(1):31-46.
[30] QIAN Z, HU W, LV Z, et al. PKM2 upregulation promotes malignancy and indicates poor prognosis for intrahepatic cholangiocarcinoma[J]. Clin Res Hepatol Gastroenterol, 2020, 44(2):162-173.
[31] LIANG Q, LIU H, ZHANG T, et al. Serum metabolomics uncovering specific metabolite signatures of intra- and extrahepatic cholangiocarcinoma[J]. Mol Biosyst, 2016, 2(2):334-340.
[32] URMAN J M, HERRANZ J M, URIARTE I, et al. Pilot multi-omic analysis of human bile from benign and malignant biliary strictures: a machine-learning approach[J]. Cancers (Basel), 2020, 12(6):1644.
[33] BANALES J M, I?ARRAIRAEGUI M, ARBELAIZ A, et al. Serum metabolites as diagnostic biomarkers for cholangiocarcinoma, hepatocellular carcinoma, and primary sclerosing cholangitis[J]. Hepatology, 2019, 70(2):547-562.
[34] ELHANANI O, BEN-URI R, KEREN L. Spatial profiling technologies illuminate the tumor microenvironment[J]. Cancer Cell, 2023, 41(3):404-420.
[35] HUANG Y H, ZHANG C Z, HUANG Q S, et al. Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma[J]. J Hepatol, 2021, 74(4):838-849.
[36] JOB S, RAPOUD D, DOS SANTOS A, et al. Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma[J]. Hepatology, 2020, 72(3):965-981.
[37] MARTIN-SERRANO M A, KEPECS B, TORRES-MARTIN M, et al. Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications[J]. Gut, 2023, 72(4):736-748.
[38] NAKAMURA H, ARAI Y, TOTOKI Y, et al. Genomic spectra of biliary tract cancer[J]. Nat Genet, 2015, 47(9):1003-1010.
[39] NEPAL C, ZHU B, O'ROURKE C J, et al. Integrative molecular characterisation of gallbladder cancer reveals micro-environment-associated subtypes[J]. J Hepatol, 2021, 74(5):1132-1144.
[40] JUSAKUL A, CUTCUTACHE I, YONG C H, et al. Wholegenome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma[J]. Cancer Discov, 2017, 7(10): 1116-1135.
[41] ABOU-ALFA G K, MACARULLA T, JAVLE M M, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study[J]. Lancet Oncol, 2020, 21(6):796-807.
[42] ABOU-ALFA G K, SAHAI V, HOLLEBECQUE A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study[J]. Lancet Oncol, 2020, 21(5):671-684.
[43] OHBA A, MORIZANE C, UENO M, et al. Multicenter phase Ⅱ trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial[J]. Future Oncol, 2022, 18(19):2351-2360.
[44] AROZARENA I, WELLBROCK C. Overcoming resistance to BRAF inhibitors[J]. Ann Transl Med, 2017, 5(19):387.
[45] DOEBELE R C, DRILON A, PAZ-ARES L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials[J]. Lancet Oncol, 2020, 21(2):271-282.
Options
Outlines

/

〈 〉